Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 143

Sort by

Sort Order Select

Journal Articles

Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

Pilar Lancho Lavilla, Miguel Lopez-Esteban, Javier Ortiz-Alonso, Gracia Fajardo-Tórtola, Patricia Font Lopez, Marina Gomez Llobell, Jose Antonio Serra Resach, Ana Perez-Corral, Isabel Regalado Artamendi, Mónica Ballesteros Andrés, Carolina Martinez-Laperche, Gloria Figaredo Garcia-Mina, Raquel Fernández González, Carlos Jiménez, Diego Conde Royo, Cristina Pascual Izquierdo, María Teresa Vidán, Ramon García-Sanz, Gabriela Rodriguez Macias

Blood (2024) 144 (Supplement 1): 5050.

https://doi.org/10.1182/blood-2024-203872

Published: 2024

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Ramon Garcia-Sanz, Anna Sureda Balari, Eva Domingo Domenech, Francisco Javier Capote Huelva, Antonio Gutierrez, Antonia Rodriguez Izquierdo, Marta Grande De Domingo, Lourdes Baeza

Blood (2024) 144 (Supplement 1): 2376.

https://doi.org/10.1182/blood-2024-193585

Published: 2024

Journal Articles

Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies

Blood (2024) 144 (Supplement 1): 1879.

https://doi.org/10.1182/blood-2024-201435

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Blood (2024) 144 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2024-197940

Published: 2024

Journal Articles

Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

Blood (2024) 144 (Supplement 1): 3297.

https://doi.org/10.1182/blood-2024-198382

Published: 2024

Journal Articles

Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals

Manuel Jorge Fernández Villalobos, Javier Ortiz, Angela Figuera Alvarez, Carlos De Miguel, Almudena De Laiglesia, Virginia Pradillo Fernandez, Marina Diaz Beya, Jordi Esteve, Marta Polo, Mayte Olave, Maria del Mar Moles, Amparo Pimentel, Ramon Garcia-Sanz, Gabriela Rodriguez Macias

Blood (2024) 144 (Supplement 1): 4285.

https://doi.org/10.1182/blood-2024-209528

Published: 2024

Journal Articles

At-Home Allogeneic Stem Cell Transplantation: A Single Centre Experience

Ignacio Gómez-Centurión, Carmen García Menéndez, Rebeca Bailen, Paula Fernández-Caldas, Lucia Castilla Garcia, Pablo Silva, Carmen López Fresneña, Ramon García, Mi Kwon

Blood (2024) 144 (Supplement 1): 4872.

https://doi.org/10.1182/blood-2024-210530

Published: 2024

Journal Articles

Outcomes of Allogeneic Transplantation with Clofarabine and Post-Transplant Cyclophosphamide-Based Conditioning in Patients with Very High-Risk Acute Myeloid Leukemia

Lucia Castilla Garcia, Rebeca Bailen, Ignacio Alberto Gomez Centurion Luna, Paula Fernández-Caldas, Pablo Silva De Tena, Carolina Martinez-Laperche, Javier Anguita, Ramon Garcia-Sanz, Mi Kwon

Blood (2024) 144 (Supplement 1): 4889.

https://doi.org/10.1182/blood-2024-210237

Published: 2024

Journal Articles

BONE Marrow Chimerism and Measurable Residual Disease Analysis Interplay: Impact on Prognosis of ACUTE Myeloid Leukemia Undergoing STEM Celltransplatation

Manuel Jorge Fernández Villalobos, Ignacio Alberto Gomez Centurion Luna, Paula Fernández-Caldas, Rebeca Bailen, Pablo Silva, Lucia Castilla Garcia, Ana Perez-Corral, Carolina Martinez-Laperche, Ramon Garcia-Sanz, Mi Kwon

Blood (2024) 144 (Supplement 1): 7447.

https://doi.org/10.1182/blood-2024-210898

Published: 2024

Journal Articles

Transcriptomic Signatures of T and CAR T Cells Aspredictors of Treatment Outcomes Inrelapsed/Refractory Large Diffuse B Cell Lymphoma

Ismael De La Iglesia San Sebastián, Sara Fernández de Córdoba-Oñate, Mariana Bastos-Oreiro, Raquel Fernández González, Javier Anguita, Ignacio Gómez-Centurión, Rebeca Bailen, Mi Kwon, Ramon Garcia-Sanz, Ismael Buño, Carolina Martinez-Laperche

Blood (2024) 144 (Supplement 1): 7150.

https://doi.org/10.1182/blood-2024-207145

Published: 2024

Journal Articles

Predictive Value of Liver Sitffness Measurement for Early Diagnosis of Veno-Occlusive Disease and Final Stem-Cell Outcomes

Manuel Jorge Fernández Villalobos, Rebeca Bailen, Ignacio Alberto Gomez Centurion Luna, Pablo Silva, Lucia Castilla Garcia, Paula Fernández-Caldas, Sonia Alonso, Adriana Ahumada, Carlos Iniesta, Rafael Bañares, Ramon Garcia-Sanz, Mi Kwon

Blood (2024) 144 (Supplement 1): 2113.

https://doi.org/10.1182/blood-2024-209475

Published: 2024

Journal Articles

Improved Genetic Characterization of Aggressive B-Cell Lymphoma at Diagnosis Using Next-Generation Sequencing

Mariana Bastos-Oreiro, Ismael De La Iglesia, Maria Chicano, Marina Gomez Llobell, Francisco Diaz Crespo, Paula Fernández Caldas-González, Juan Carlos Triviño, Raquel Fernandez, Ramon Garcia-Sanz, Ismael Buño, Carolina Martinez-Laperche

Blood (2024) 144 (Supplement 1): 6229.

https://doi.org/10.1182/blood-2024-208216

Published: 2024

Journal Articles

Upfront CPX-351 Induction at 8 Spanish Hospital. Efficacy of CPX-351 in Everyday Clinical Practice and Increased Insight into Its Use in Younger Adults

Manuel Jorge Fernández Villalobos, Javier Ortiz, Angela Figuera Alvarez, Almudena De Laiglesia, Carlos De Miguel, Virginia Pradillo Fernandez, Jordi Esteve, Marina Diaz Beya, Marta Polo, Mayte Olave, Maria del Mar Moles, Amparo Pimentel, Ramon Garcia-Sanz, Gabriela Rodriguez Macias

Blood (2024) 144 (Supplement 1): 6034.

https://doi.org/10.1182/blood-2024-202036

Published: 2024

Journal Articles

Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy

Carolina Martinez-Laperche, Gonzalo Del Campo-Balguerias, Ismael De La Iglesia San Sebastián, Juan Carlos Triviño, Francisco Diaz Crespo, Rebeca Bailen, Raquel Fernandez-Gonzalez, Sara Fernandez-de Córdoba, Ana Jiménez Ubieto, Alejandro Martín-Muñoz, Paula Fernández Caldas-González, Ignacio Gómez-Centurión, Mi Kwon, Javier Anguita, Ramon García-Sanz, Ismael Buño, Mariana Bastos-Oreiro

Blood (2024) 144 (Supplement 1): 2044.

https://doi.org/10.1182/blood-2024-209913

Published: 2024

Journal Articles

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Blood (2023) 142 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2023-189581

Published: 2023

Journal Articles

Prospective Evaluation of Minimal Residual Disease in Waldenström Macroglobulinemia across Different Tissues and Treatments: Results of the “BIO-WM” Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 1621.

https://doi.org/10.1182/blood-2023-181731

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

Journal Articles

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

David Lavie, John Timmerman, Ramón García-Sanz, Won Seog Kim, Tae Min Kim, Abraham Avigdor, Daan Dierickx, Deepa Jagadeesh, Daniel L. Molin, Muhit Ozcan, Omur Gokmen Sevindik, Hayder Saeed, Yulia Sidi, Pallavi Pillai, Patricia Marinello, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2023-182119

Published: 2023

NARROW

Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals

At-Home Allogeneic Stem Cell Transplantation: A Single Centre Experience

Outcomes of Allogeneic Transplantation with Clofarabine and Post-Transplant Cyclophosphamide-Based Conditioning in Patients with Very High-Risk Acute Myeloid Leukemia

BONE Marrow Chimerism and Measurable Residual Disease Analysis Interplay: Impact on Prognosis of ACUTE Myeloid Leukemia Undergoing STEM Celltransplatation

Transcriptomic Signatures of T and CAR T Cells Aspredictors of Treatment Outcomes Inrelapsed/Refractory Large Diffuse B Cell Lymphoma

Predictive Value of Liver Sitffness Measurement for Early Diagnosis of Veno-Occlusive Disease and Final Stem-Cell Outcomes

Improved Genetic Characterization of Aggressive B-Cell Lymphoma at Diagnosis Using Next-Generation Sequencing

Upfront CPX-351 Induction at 8 Spanish Hospital. Efficacy of CPX-351 in Everyday Clinical Practice and Increased Insight into Its Use in Younger Adults

Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Prospective Evaluation of Minimal Residual Disease in Waldenström Macroglobulinemia across Different Tissues and Treatments: Results of the “BIO-WM” Trial of the Fondazione Italiana Linfomi (FIL)

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only